Request Demo
Last update 13 Sep 2025
Adalimumab Biosimilar(Nippon Kayaku)
Last update 13 Sep 2025
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms- |
Target |
Action inhibitors |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (25 Sep 2023), |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 26792L
The sequence is quoted from: *****
Sequence Code 88699H
The sequence is quoted from: *****
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Non-radiographic axial spondyloarthritis | Japan | 19 Mar 2025 | |
| Ankylosing Spondylitis | Japan | 25 Sep 2023 | |
| Arthritis, Psoriatic | Japan | 25 Sep 2023 | |
| Behcet Syndrome | Japan | 25 Sep 2023 | |
| Colitis, Ulcerative | Japan | 25 Sep 2023 | |
| Crohn Disease | Japan | 25 Sep 2023 | |
| Panuveitis | Japan | 25 Sep 2023 | |
| Plaque psoriasis | Japan | 25 Sep 2023 | |
| Polyarticular Juvenile Idiopathic Arthritis | Japan | 25 Sep 2023 | |
| Pustular psoriasis | Japan | 25 Sep 2023 | |
| Rheumatoid Arthritis | Japan | 25 Sep 2023 | |
| Uveitis, Intermediate | Japan | 25 Sep 2023 | |
| Uveitis, Posterior | Japan | 25 Sep 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free